Cognition Therapeutics
CGTX
51 hedge funds and large institutions have $4.89M invested in Cognition Therapeutics in 2025 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
13% more funds holding
Funds holding: 45 → 51 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7.92% less ownership
Funds ownership: 26.69% → 18.76% (-7.9%)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
37% less capital invested
Capital invested by funds: $7.78M → $4.89M (-$2.89M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$527K |
| 2 |
CM
CM Management
Gulf Breeze,
Florida
|
+$118K |
| 3 |
VPIM
Vanguard Personalized Indexing Management
Oakland,
California
|
+$32.9K |
| 4 |
EFS
Essex Financial Services
Essex,
Connecticut
|
+$23.3K |
| 5 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
+$22.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$351K |
| 2 |
VF
Virtu Financial
New York
|
-$56K |
| 3 |
VC
Voss Capital
Houston,
Texas
|
-$29.4K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$28.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$24.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
UBS Group
Zurich,
Switzerland
| – | -$24.2K | -41,111 | -100% |
|
|
BCM
52
Bridgeway Capital Management
Houston,
Texas
| – | -$22.4K | -31,874 | Closed |
|
53
Jane Street
New York
| – | -$7.04K | -10,040 | Closed |
|
54
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$235 | +400 | New |
|
CGTX Hedge Fund Activity: Q1 2025 in Review
51 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q1 2025, worth a combined $4.89M — down 37% from $7.78M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CGTX positions and 4 closed out — a net gain of 7 holders — while 10 added to existing stakes and 12 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $527K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $351K sold.
- 51 institutional investors held Cognition Therapeutics (CGTX) as of Q1 2025, up from 45 in Q4 2024.
- Funds reported $4.89M of Cognition Therapeutics stock for Q1 2025, down 37% quarter-over-quarter.
- 11 funds opened new Cognition Therapeutics positions in Q1 2025 and 4 closed out, a net change of +7 holders.
- The largest Cognition Therapeutics buyer in Q1 2025 was Acadian Asset Management, an estimated $527K added.
- The largest Cognition Therapeutics seller in Q1 2025 was Alyeska Investment Group, an estimated $351K sold.
Based on aggregated 13F filings for Q1 2025.